It has been widely demonstrated that TP53 loss of function increases genomic instability and generates DNA damage, which links TP53 deficiency with higher TMB and correlates it with clinical benefit in advanced NSCLC patients treated with ICIs [50]. Here, TP53 is linked to non-small cell lung carcinoma.